uploads/2018/03/pill-1884777_1280.jpg

Analysts’ Recommendations for Xencor and Its Peers in March

By

Updated

Company overview

Xencor (XNCR) is a clinical-stage biopharmaceutical company with a focus on the discovery and development of monoclonal antibody therapeutics for the treatment of severe and life-threatening diseases. 

Xencor’s proprietary technology platform, XmAb, enables it to create antibody product candidates for the treatment of autoimmune and allergic diseases.

Article continues below advertisement

Analysts’ recommendations

Of the six analysts covering Xencor in March 2018, three have given the stock “strong buy” ratings, and two have given it “buy” ratings, while one analyst has given it a “hold” rating. The mean rating for the stock is 1.67, and its target price is $36.67.

Peers’ ratings

Of the 23 analysts covering AbbVie (ABBV) in March 2018, four analysts have given the stock “strong buy” ratings, and six have given it “buy” ratings. Twelve analysts have given AbbVie “hold” ratings, while one has given it a “sell” rating. The mean rating for the stock is 2.43, and its target price is $125.9.

Of the 33 analysts covering Biogen (BIIB) in March 2018, 24 have given the stock “buy” or higher ratings, while nine have given it “hold” ratings. The mean rating for the stock is 2, and its target price is $378.9.

Of the eight analysts covering Novavax (NVAX) in March 2018, two analysts have given the stock “strong buy” ratings, and one has given it a “buy” rating. Four analysts have given Novavax “hold” ratings, while one analyst has given it a “sell” rating. The mean rating for the stock is 2.5, and its target price is $3.83.

In the next article, we’ll take a look at Xencor’s product pipeline.

Advertisement

More From Market Realist